COLORADO SPRINGS, Colo.,
Feb. 4, 2014 /PRNewswire/ -- Endocan
Corporation (OTC: ENDO), a U.S. Company specializing in cannabis,
hemp, and cannabinoid formulation-based health and wellness
solutions, is pleased that the U.S. Congress and President Obama
appear on the verge of approving the first key law to legalize hemp
cultivation and advanced research on a federal level, creating
substantial economic opportunities going forward.
As announced on January 29, 2014,
the U.S. House of Representatives approved the "farm bill" that
contains a provision for certain cultivation of industrial hemp for
research in a number of U.S. states. Passage of the farm bill
is the beginning step towards legalization of commercial hemp grows
in the U.S. The Senate is expected to approve the measure as
soon as today, and President Obama has declared that he will sign
the bill into law, changing the legal landscape for the entire hemp
industry.
"Hemp has a variety of uses: from skin care products and
cosmetics to clothing and food. The passing of the pending
farm bill by the House -- and the bill's strong likelihood of
becoming law in the next days -- takes our state-by-state hemp
product strategy to the federal level sooner than expected.
This looks to be a game changer for our industry and for Endocan,"
said Chad S. Johnson, Chief
Operating Officer and General Counsel of Endocan
Corporation.
About Endocan Corporation
Endocan Corporation is currently developing new natural products
based on innovative formulations to utilize the unique and potent
benefits of the cannabis and hemp plants. Medicinal properties of
cannabis and hemp have been known and applied for thousands of
years. With the aid of scientific research, Endocan Corporation is
translating such knowledge into development of effective
cannabinoid formulation-based health and wellness solutions as well
as cosmeceutical, nutraceutical, and food brands throughout the
world. The Company's health and wellness, nutritional, and
cosmetics lines will address personal needs and will evolve with
the introduction of new formulations and products, advancing the
Company within the expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. The
Company does not undertake any duty nor does it intend to update
the results of these forward-looking statements.
Endocan Corporation
President
Dr. Dorothy Bray
info@endocan.com
www.endocan.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
robert.kane@endocan.com
+1.561.420.4824
SOURCE Endocan Corporation